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Abstract
Background: Human papillomavirus (HPV) and Epstein Barr virus (EBV) have been found in breast carcinomas (BCs)
around the world. In this study, fifty-five BCs from Chile were analyzed for HPV and EBV presence. In addition, HPV-
16 viral load/physical status and E6/E7 expressions were determined.
Results: The amplification of a housekeeping gene showed that 46/55 samples (84%) had amplifiable DNA. HPV-16
was detected in 4/46 BCs (8.7%) and EBV was detected in 3/46 (6.5%) BCs. The analysis of HPV-16 physical status
showed that this virus was integrated in all of the tumors with a relatively low viral load (range: 0.14 to 33.8 copies/
cell). E6 and E7 transcripts, however, were not detected in any HPV-16 positive specimens. Using a Cox-regression
model, we found a statistically significant association between EBV presence and poor survival (p = 0.013).
Conclusions: The findings in this study suggest that it is unlikely that HPV and/or EBV play a direct role in the
etiology of BC.
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Background
Breast cancer (BC) is a leading cause of death in women
around the world. In Chile, BC is the second cause of
death by cancer with a mortality rate of 11.0/100.000
habitants [1]. It is known that only 5-10% of BCs arise in
women with familial history and 90-95% are sporadic [2].
Thus, environmental factors are prominent in the etiol-
ogy of this malignancy. Viral infections are associated
with 20% of the cancer around the world. Only two
viruses, human papillomavirus (HPV) and Epstein Barr
virus (EBV) are associated with 38% of all virus-asso-
ciated neoplasia [3]. In addition, these two viruses have
been incriminated in the development of BC [4,5]. The
HPV and EBV presence in BCs is highly variable world-
wide, and their etiological role remains highly controver-
sial. HPV is the causal agent of cervix-uterine cancer and
anogenital malignancies [3]. However, HPV has been
detected in extragenital tumors such as oral, esophageal,
tonsillar, laryngeal, lungs and BC [5]. Di Lonardo was the
first reporting HPV presence in 29.4% of BCs using poly-
merase chain reaction (PCR) [6]. In addition, functional
s t u d i e sw e r em a d ei nt h ee a r l y9 0 ’s reporting that both,
HPV-16 and -18 were able to immortalize and change
the proliferative properties of epithelial breast cells [7]. In
another study, using a mouse model it was reported that
estrogen and the loss of p53 synergized to induce mam-
mary tumors in the presence of HPV [8]. On the other
hand, EBV is associated with nasopharyngeal carcinoma
and Burkitt’s lymphoma, and has been involved in the
development of a subset of gastric cancer and BCs [4].
Thus, the aim of this study was to analyze the presence
of HPV and EBV in BC from Chile, an Asia-Pacific area
country where no information about the HPV/EBV pre-
sence in BC is available. In addition, in order to shed a
light about the function of HPV in this tumor, we deter-
mined the integration status, viral load and E6/E7 tran-
scripts expression in positive cases.
Results
In this study, HPV and EBV sequences were searched in
BCs from patients living in Santiago of Chile. Fifty-five
formalin-fixed paraffin-embedded BCs from different
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extracted DNAs analyzed for integrity by amplifying a
110 bp fragment of the betaglobin gene. Forty-six sam-
ples out of 55 were betaglobin positive (84%). Using
conventional PCR for a 65 bp fragment of L1 region,
HPV was detected in 4/46 (8.7%) BCs. Using qRT-PCR
for EBV EBNA-1, EBV was present in 3/46 (6.5%) BCs.
Co-infection with both viruses was only detected in
1/46 (2.1%) cases. In addition, ISH for EBER-1 showed
that all of the BCs were EBV negative. A non-statisti-
cally significant association between HPV presence and
age, tumor size, histology and differentiation grade was
found (p = 1.000; 0.780; 1.000 and 0.721 respectively,
Table 1). HPV infection was more frequently detected
in primary tumors from patients with metastatic lymph
nodes, although it was not statistically significant (p =
0.078). On the other hand, no statistically significant
association between EBV presence and age, lymph
nodes involvement, tumor size, histology and differentia-
tion grade was found (p = 1.000, 1.000, 0.459, 0.130 and
0.255, respectively, Table 1). Using a Cox-regression
model, a statistically significant association between
EBNA-1 positivity by qRT-PCR and poor survival was
found (p = 0.013, Figure 1). The Inno-Lipa method
showed that only the HPV-16 genotype was present in
HPV positive BCs without co-infections with other HPV
genotypes. In addition, the number of copies of HPV-16
determined by real-time PCR was extremely low in 1/4
cases studied (0.14 copies/cell). In the other three cases,
the viral load was higher (1.2; 2.0 and 33.8 copies/cell,
Table 2). The absence of E2 amplification showed that
HPV-16 was completely integrated into the host genome
in all of the cases. In addition, we were unable to detect
H P V 1 6E 6a n dE 7t r a n s c r i p t si n3 / 3H P V - 1 6p o s i t i v e
cases as showed using transcriptase-reverse real-time
PCR, even though the specimens were positive for b2-
microglobulin expression (Table 2).
Discussion
The etiological role of HPV or EBV in some extragenital
tumors is under intense debate. In this report, the pre-
sence of HPV and EBV was evaluated in BCs from
Chile, a Latin American country from the Pacific Ocean
area. Our findings showed that HPV and EBV preva-
lence in BCs was relatively low since these viruses were
present in 8.7% and 6.5% of breast tumors, respectively.
T h eh i g h - r i s kH P V - 1 6 ,t h eg e n o t y p em o s tf r e q u e n t l y
detected in cervix uterine cancer and extragenital malig-
nancies in Chile and in the world [9,10] was the only
genotype identified in HPV positive BCs. However, the
presence of HPV genomes is not a sufficient condition
to establish a causal relationship. For this reason, we
investigated the physical status of HPV and the presence
of E6/E7 transcripts into the BC tumors. Thus, we
found that HPV-16 was integrated into the host genome
in all of the cases.
Table 1 Relationship between clinicopathological features of breast carcinomas and HPV/EBV presence
HPV (L1) EBV (EBNA-1)
All HPV+ HPV- p-value EBV+ EBV- p-value
N (%) N(%) N(%) N(%) N(%)
Age 1.000 1.000
< 65 years 34 3 (9) 31 (91) 2 (6) 32 (94)
> 65 years 12 1 (8) 11 (92) 1 (8) 11 (92)
Lymph nodes 0.078 1.000
negative 32 1 (3) 31 (97) 2 (6) 30 (94)
positive 14 3 (21) 11 (79) 1 (7) 13 (93)
Tumor size 0.780 0.459
< 2 cm 7 0 (0) 7 (100) 1 (14) 6 (86)
2-5 cm 31 4 (13) 27 (87) 2 (6) 29 (94)
> 5 cm 8 0 (0) 8 (100) 0 (0) 8 (100)
Histology 1.000 0.130
ductal 42 4 (10) 38 (90) 2 (5) 40 (95)
lobulillar 1 0 (0) 1 (100) 1 (100) 0 (0)
duct/lob 2 0 (0) 2 (100) 0 (0) 2 (100)
mucinoso 1 0 (0) 1 (100) 0 (0) 1 (100)
Differentiation 0.721 0.255
well 3 0 (0) 3 (100) 1 (33) 2 (67)
moderately 17 1 (6) 16 (94) 1 (6) 16 (94)
poor 23 3 (13) 20 (87) 1 (4) 22 (96)
unknown 3 0 (0) 3 (100) 0 (0) 3 (100)
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suggesting a causal association. Hennig et al. proposed
that HPV can be transported by circulation (blood-
stream/lymphatic system) from cervix to the breast [11].
In addition, it has been reported the presence of HPV-
6/11 and other papillomaviruses in nipple and tumoral
tissue from patients with BC, even though high-risk
HPV was present in a low proportion of cases [12]. In
Asia, it has been reported a 20% of high-risk HPV in
breast tumors from Japanese women and HPV-16 was
the most frequent HPV genotype that was integrated
into the host genome with a low viral load [13]. In Latin
America, only three studies have been reported: in Brazil
it was reported HPV-16/18 presence in 24.8% of BCs
[14] and recently it was published that 79 analyzed BCs
were negative for HPV-6, 11, 16 and 18 [15]. In Mexico,
HPV was found in 29.4% of BC, being HPV-16 the most
prevalent genotype [16]. However, in the same country,
HPV was detected in 10% of 60 BCs [17]. In this last
study, HPV was found integrated with a low viral load.
In Oceania (Australia), it has been reported a study
using In situ PCR for the successful detection of HPV
in BCs. High-risk HPV was detected in the nucleus of
11/43 (25.6%) BCs [18]. On the other hand, HPV-18
genotype was frequently found in Australian BCs [19].
The loss of E2 gene function by HPV integration is
known to be one of the major genetic events facilitating
transformation and transition to malignancy [9]. The E2
loss allows abnormal expression of E6 and E7 oncopro-
teins [20]. The mechanism of high-risk HPV-mediated
oncogenesis involves the interaction of E6 oncoprotein
with the p53 tumor suppressor protein and the E6-asso-
ciated protein for induction of proteasomal-dependant
p53 degradation [3]. In addition, the high-risk HPV E7
binding to pRb protein induces E2F releasing and over-
expression of p16
INK4a by a negative feedback mechan-
ism [21]. High-risk HPVs are frequently integrated in
high-grade cervical intraepithelial neoplasia lesions and
low-risk HPVs are frequently present in an episomal
form in low-grade or benign lesions [22]. The analytical
approach used in this report, considers HPV-16 inte-
grated when E2 gene is not amplified using quantitative
r e a l - t i m eP C R .T h i si sa ni n d irect method, based in the
frequent E2 disruption when HPV is integrated into the
host genome. However, HPV is able to integrate disrupt-
ing other regions as E1 [23]. So, when E2 is successfully
amplified is not possible discard HPV-16 integration.
However, we were unable to amplify a fragment of E2
gene in four cases that previously were positive for
HPV-16 presence. Thus, E2 loss by integration is the
biological possibility that explains these results.
Even though, HPV-16 was present and integrated in
BCs, we were unable to detect E6 and E7 transcript
expressions in the specimens. The successful amplification
of a fragment of b2-microglobulin was used as control of
cDNA preparation and amplification from paraffin-
embedded tissues. It has been reported that in general
HPV load in extragenital tumors is heterogeneous and
lower that in cervical cancer [13,24,25] so it was expected
that E6/E7 transcript levels were very low too, in concor-
dance with the viral load. However, the absence of detect-
able levels of E6/E7 transcripts is a hallmark of absence of
functional activity in HPV-16 positive specimens. The
RNA obtained from paraffin-embedded cervical carcino-
mas was used as control, and we were able to detect E6/
E7 transcripts in all of them (data not shown). Curiously,
this is the first study that addresses the expression of E6
and E7 transcripts in breast carcinomas, so we cannot
Figure 1 Cox-regression survival curves. These curves were
constructed with age, number of nodes, percentage of positive
nodes, histology, differentiation and tumor size. A: EBNA-1 positive
women; B: EBNA-1 negative women.
Table 2 Physical status, viral load and E6/E7 expression in HPV-16 positive breast carcinomas
Sample E6 (copies/cell) E2 (copies/cell) E2/E6 Physical status E6/E7 transcripts
BC2 2 0 0 integrated negative
BC21 33,8 0 0 integrated ND
a
BC31 1,2 0 0 integrated negative
BC5 0,14 0 0 integrated negative
aND: non-determined (specimen exhausted)
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On the other hand, the viral load in three specimens
(higher than unity) is compatible with an eventual direct
carcinogenic role of HPV, although the absence of E6/E7
expression casts doubts about this notion. To this respect,
it is possible to speculate the possibility of a “hit and run”
mechanism of HPV action, however if HPV is related to
the initiation, promotion or progression of breast carcino-
genesis is unknown. Because PCR method is unable to
determine if HPV localizes specifically in the tumoral tis-
sue, the detected viral load in 3/4 cases allow us to specu-
late that at least tumoral cells are positive for HPV-16.
Anyway, we cannot deny the possibility that HPV infection
occurred after clonal expansion and cancer development,
involving both tumoral and non-tumoral tissue. In addi-
tion, it is known that one HPV genome per cell is enough
for neoplastic transformation as occur in SiHa cells har-
boring 1-2 HPV-16 copies/cell. Around the world, the
HPV prevalence in BCs has been shown to be highly vari-
able, ranging from 0 to 86% [26]. This difference may be
explained by variations in the methodological approaches
used to detect HPV. Moreover, PCR protocols showing a
diverse sensitivity and specificity are currently used to
determine HPV presence in tumoral tissue and a “gold
standard” protocol has not been defined. However, our
analytical approach has been widely used by us and was
previously reported by others [13].
On the other hand, there is a relative consensus that
for detection of EBV latent infection, the “gold standard”
method is ISH for EBER-1 [27]. Interestingly, we
detected three positive specimens using qRT-PCR for
EBNA-1 and using ISH for EBER-1, the cases were
negative. This discrepancy might be caused by differ-
ences in sensitivity of these methods or very low levels
of EBER-1 expression in EBV infected cells. EBERs are
necessary for the maintenance of malignant phenotypes
of B lymphocyte cells but is unknown if are ever
expressed in BC cells [28]. Recently, it has been reported
a 55% of EBV presence in BCs from India [29]. Interest-
ingly, the authors evaluated EBNA-1 expression using
immunohistochemistry (IHC) and they compared with
serology in women with cancer and controls. Unfortu-
nately, the authors did not compare their results with
EBER-1 detection in the same specimens. In BC, since
the first study in 1993 reporting no detection of EBV in
BCs [30], EBV presence has been consistently reported
in a plethora of other studies [29,31-36]. However, EBV
has not been detected in other reports around the world
[37-40]. In this study, using a Cox-regression model we
found a statistically significant association between EBV
EBNA-1 positivity and poor survival. Even though the
sample size was low, this data is in agreement with a
previous report where a relationship between poor sur-
vival and EBV presence was found [41]. The molecular
mechanism involved in poor survival in EBV- associated
BC remains to be investigated. It is necessary to appoint
that is not strictly necessary that a virus be directly
involved as etiological agent to produce molecular
alterations in the behavior of some tumor or progression
of the disease. In fact, HCMV, another persistent virus,
has been detected in some tumors where the virus is
able to alter the host response, specifically through
immune response modulation [42]. However, how HPV
or EBV may potentially be involved in tumor modula-
tion and consequently are associated with outcome or
prognostic warrants more investigation.
In conclusion, we reported here that HPV and EBV
prevalence in breast cancer from Chile is relatively low,
thus a possible direct etiological role of these virus is
unlikely. However, additional studies are warranted to
elucidate the function of HPV/EBV in a subset of breast
carcinomas from Chile.
Methods
Study subjects
Fifty-five BCs from patients of different Hospitals in
S a n t i a g oo fC h i l ew e r ec o n s i d e r e df o rt h i ss t u d y .T h e
Hospitals were Las Condes Clinic; San Juan de Dios
Hospital; Instituto Nacional del Cáncer; San Borja
Arriaran Hospital; José Joaquín Aguirre Hospital; Arturo
Lopez Perez Foundation and Santa María Clinic. The
average age of the patients was 58.7 years (range: 48.1-
69.3). The histological types of BC were: 48 ductal, 6
lobulillar and 1 mucinous. In the present study, histolo-
gical classification was made using the guidelines of the
Japan Cancer Society [43], which follows the WHO clas-
sification. The Grupo Oncológico Cooperativo Chileno
de Investigación (GOCCHI) approved this study.
DNA extraction, HPV detection and genotyping
Sections of 10 μm thickness were cut and collected in
sterile tubes. For DNA extraction, each sample was trea-
ted with 1 mL of xylene and subsequently washed with 1
mL of ethanol. The sediment was resuspended in 50 mM
Tris-Cl pH 8.0, 1 mM EDTA, pH 8.0, and 0.5% Tween 20
containing 200 μgmL
-1 of proteinase K (Invitrogen Corp.,
Carlsbad, CA, USA) and incubated overnight at 56°C.
The solution was heated at 100°C for 10 min and subse-
quently the DNA was purified by phenol-chloroform
extraction and precipitated with cold ethanol. DNA qual-
ity was tested by PCR for betaglobin using PCO3 5’-
ACACAACTGTGTTCACTAGC-3’ and PCO4 5’-
CAACTTCATCCACGTTCACC-3’ primers under the
following PCR conditions: denaturation at 95°C for 15
min, 40 cycles with the cycling profile of 95°C for 1 min,
52°C for 1 min, 72°C for 1 min and final extension at 72°
C for 5 min. To detect HPV genomes, broad-spectrum
SPF10-biotinylated primers were used. The PCR
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4% agarose gel and visualized under UV radiation with
ethidium bromide staining. HPV genotyping was per-
formed using the Inno-Lipa HPV Genotyping V2 test
(Innogenetics, Ghent, Belgium) [44]. As negative con-
trols, paraffin sections without tissue and distilled water
were used for procedures of DNA extraction and PCR,
respectively. Full genomes of HPV-16 and HPV-18
cloned in pUC19 plasmid (kindly given by Dr. Massimo
Tommasino, IARC, Lyon, France) were used as positive
controls for HPV amplification.
Quantitative real-time PCR (qRT-PCR)
To determine the presence, physical status and viral load
of HPV-16, real-time PCR was performed with the ABI
Prism 7700 Sequence Detection System (Applied Biosys-
tems, Foster City, CA, USA) and 2 × QuantiTect SYBR
Green PCR kit (Qiagen, Hilden, Germany). The HPV-16
primers for E6 ORF amplification were as follows: E6F: 5’-
GAGAAACTGCAATGTTTCAGGACC-3’ and E6R: 5’-
TGTATAGTTGTTTGCAGCTCTGTGC-3’. The HPV-16
primers for E2 ORF amplification were as follows: E2F: 5’-
AACGAAGTATCCTCTCCTGAAATTATTAG-3’ and
E2R: 5’-CCAAGGCGACGGCTTTG-3’.T h eP C Rc o n d i -
tions were 2 min at 50°C, 15 min at 95°C, and a two-step
cycle of 95°C for 15 s, and 60°C for 60 s for a total of 40
cycles [45]. The sizes of the E6 and E2 products were 81
and 76 bp, respectively. Dilutions of the full-length HPV-
16 genome cloned in pBR-322 vector, from 86 to 862 mil-
lion copies per reaction, served as a standard for calibra-
tion curves for E2 and E6 genes. Linear plots of the log of
copy number vs. numbers of threshold cycle were consis-
tently obtained for both genes. As positive control, the cell
line SiHa containing 1 copy of HPV-16 per cell was used.
Real-time PCR for a betaglobin gene fragment was per-
formed by the 2 × QuantiTect SYBR Green PCR kit (Qia-
gen) using PC03/PC04 to adjust the differences in the
amount of input genomic DNA between samples. A
seven-fold dilution series of a human DNA control (Dynal,
UK Ltd, Bromborough, Wirral, Merseyside, UK) was used
to generate the standard curve. The amount of betaglobin
DNA present in each sample was divided by the weight of
one genome equivalent (that is, 6.6 pg per cell) and a fac-
tor of 2 (as there are two copies of b-globin DNA/genome
equivalent or cell) to obtain the number of genome
equivalents. For EBV detection, the PCR conditions were
2 min at 50°C, 15 min at 95°C, and a two-step cycle of 95°
C for 15 s and 60°C for 60 s for a total of 40 cycles. The
primers sequence was as follows: EBV-F 5’-TACAG-
GACCTGGAAATGGCC-3’ and EBV-R: 5’-TCTTTG
AGGTCCACTGCCG-3’. The amplified fragments in posi-
tive specimens were characterized by melting analysis and
checked by agarose gel electrophoresis.
qRT-PCR for HPV-16 E6 and E7 transcripts
The RNA purification was carrying out using the High
Pure RNA paraffin kit (Roche), according to instruc-
tions of the manufacturer. The obtained RNA was
resuspended in 50 μLo fT E( 1 0m MT r i s - C l ,1m M
EDTA) and stored at -80°C until use. The cDNA pre-
paration was made as follows: 100 ng of purified RNA
were transformed to cDNA using RNAsin 1 U/μL
(Promega, USA); 1× buffer TR (Promega, USA); 10 μg/
μL random primers (Promega, USA); 20 U/μLM M L V
(Promega, USA) and 2 mM dNTPs in a final volume
of 20 μL. The reaction mixture was incubated at 37°C
for 1 h, 70°C for 15 min and stored at -20°C. Ten
microliters of cDNA were used for qRT-PCR. The
amplification reaction was carrying out separately for
HPV-16 E6 and E7 transcripts using the SensimixSYBR
(Bioline) kit in a final volume of 25 μL. For E6, the
reaction mixture was composed by 1X SensiMix, 0.8
μM primers and 5 mM MgCl2. The conditions of
amplification were: denaturation at 95°C for 10 min,
45 cycles of 95°C for 15 s, 55°C for 20 s, 72°C for 20 s
and a final extension at 72°C for 20 s. The sequence of
primers was: E6F: 5’-CAACAAACCGTTGTGTGAT-3’;
E6R: 5’-CGTGTTCTTGATGATCTGC-3’.Am e l t i n g
curve analysis between 62°C to 95°C with a variation
of 0.5°C was made. The melting temperature (Tm) of
the amplification product from a positive control was
79.85°C. For E7, the reaction mixture was composed
by 1X SensiMix, 0.8 μM primers and 3 mM MgCl2.
The conditions of amplification were initial denatura-
tion at 95°C for 10 min followed by 45 cycles consist-
ing of denaturation at 95°C for 15 s, annealing at 57°C
for 20 s and extension at 72°C for 20 s. The sequence
of primers was E7F: ATGCATGGAGATACACCTAC;
E7R: 5’-CATTAACAGGTCTTCCAAAG-3’.T h ea m p l i -
fication of b2-microbulin gene was carrying out as fol-
low: 0.8 μMP r i m e rF ;0 . 8μM primer R, 5 mM MgCl2,
1X Sensimix and 50 ng cDNA. The amplification pro-
gram was initial denaturation at 95°C for 10 min, fol-
lowed by 45 cycles consisting of denaturation at 95°C
for 15 s, annealing at 55°C for 20 s and extension at
72°C for 20 s. The sequence of primers was: B2MF: 5’-
TGTAAGCAGCATCATGGA-3’ and B2MR: 5’-AGTG-
TAAGTGTATAAGCATATCAA-3’. The melting point
of the amplified product was 81.15°C. All the amplifi-
cations were made using Rotor Gene 6000 (Corbett
Research) real-time PCR equipment.
Tissue microarray (TMA) construction
Fifty-seven specimens of BC were used to construct a
tissue array as previously described [46]. The tumoral
area of the clinical specimens was selected by experi-
enced pathologists (LS, AC).
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In situ hybridization (ISH) with a complementary
digoxigenin-labeled 30-base probe was used to detect
EBER-1 expression according to the procedure pre-
viously published [27]. Briefly, 4-5-μms e c t i o n s
mounted on silane-coated glass slides were prepared.
The tissue on the slides (tissue array) was deparaffi-
nized, rehydrated, predigested with Pronase, prehybri-
dized, and then hybridized overnight at 37°C with 0.5
ng digoxigenin-labeled probes. The hybridization signal
was detected by an anti-digoxigenin antibody-alkaline
phosphatase conjugate. Sections from a patient with
known EBER-positive gastric carcinoma were used as
positive controls, and sensep r o b et oE B E R - 1w a su s e d
as negative control.
Statistical analysis
Fisher’se x a c tt e s tw a su s e df o rd e t e r m i n ed i f f e r e n c e s
between groups. P-value < 0.05 was considered statisti-
cally significant. For survival analysis, a Cox-regression
model was used.
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